Avalo Therapeutics Added to Russell 2000 and 3000 Indexes

Key Facts

In a move that boosts visibility for small-cap stocks in U.S. markets, Avalo Therapeutics (AVTX) announced it will be added to the Russell 2000 and Russell 3000 indexes, effective after market close on June 26, 2026. The inclusion follows the periodic reconstitution of Russell indexes based on market capitalization and liquidity criteria, which typically drives passive fund buying.

Being added to both the small-cap Russell 2000 and the broad-market Russell 3000 makes the stock a target for passive inflows from index-tracking funds. AVTX closed at $18.00 on June 25, 2026, with a trading range of $17.89–$18.69, per market data. Despite the company's small market cap, the inclusion could improve investor appetite for emerging biotech names.

In the near term, traders will watch for increased trading volumes post-inclusion, as newly added Russell stocks often see a liquidity boost. AVTX currently trades at $18.00 (close June 25, 2026), with nearby support at the session low of $17.89. While no direct economic catalysts are imminent for the stock, the annual index reconstitution itself serves as a key short-term catalyst.